PitchSend

Nuvectis Pharma Investor Presentation Deck

Substantial Antitumor Activity in Additional ARID1a- Mutated Solid Tumors Additional potential development opportunities SNU-1 Model (Gastric Carcinoma) (աա) Tumor Volume 350 300 250 200 150 100 50 Baseline Vehicle NXP800 (35 mg/kg) Day 5 NuvectisPharma, Inc. Day 7 Day 12 Day 15 Day16 Day 19 Day 21 Day 23 Day 26 Day 28 Disease Gastric Carcinoma Est. Total Incidence (US) a 26,380 a. Based on data from the American Cancer Society, 2022 Est. # of Patients w/ ARID1 a Deficiency 6,595 11

View entire presentation